Cargando…

Pharmacokinetically guided phase I trial of topotecan and etoposide phosphate in recurrent ovarian cancer

A pharmacokinetically guided phase I study of topotecan and etoposide phosphate was conducted in recurrent ovarian cancer. The scheduling of the topoisomerase I and II inhibitors was determined using in vitro activity data. All patients had recurrent disease following prior platinum-containing chemo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Levitt, N C, Propper, D J, Madhusudan, S, Braybrooke, J P, Echeta, C, te Poele, R, Davies, S L, Flanagan, E, Hickson, I D, Joel, S, Ganesan, T S
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2005
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361471/ https://www.ncbi.nlm.nih.gov/pubmed/15956976 http://dx.doi.org/10.1038/sj.bjc.6602657

Ejemplares similares

Randomized comparison of etoposide pharmacokinetics after oral etoposide phosphate and oral etoposide.
por: de Jong, R. S., et al.
Publicado: (1997)

Phase I and pharmacological study of sequential intravenous topotecan and oral etoposide.
por: Herben, V. M., et al.
Publicado: (1997)

A phase I clinical trial of continual alternating etoposide and topotecan in refractory solid tumours
por: Penson, R T, et al.
Publicado: (2005)

Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor.
por: Schellens, J. H., et al.
Publicado: (1996)

Conversion of the prodrug etoposide phosphate to etoposide in gastric juice and bile.
por: de Jong, R. S., et al.
Publicado: (1997)

A phase I and pharmacokinetic study of intraperitoneal topotecan
por: Hofstra, L S, et al.
Publicado: (2001)

Phase II study of second-line therapy with DTIC, BCNU, cisplatin and tamoxifen (Dartmouth regimen) chemotherapy in patients with malignant melanoma previously treated with dacarbazine
por: Propper, D J, et al.
Publicado: (2000)

Metronomic Chemotherapy Based on Topotecan or Topotecan and Cyclophosphamide Combination (CyTo) in Advanced, Pretreated Ovarian Cancer
por: Wysocki, Piotr J., et al.
Publicado: (2023)

Safe administration of etoposide phosphate after hypersensitivity reaction to intravenous etoposide
por: Siderov, J, et al.
Publicado: (2002)

Factors affecting pharmacokinetic variability of oral topotecan: a population analysis
por: Léger, F, et al.
Publicado: (2004)

Phase II study of the oxygen saturation curve left shifting agent BW12C in combination with the hypoxia activated drug mitomycin C in advanced colorectal cancer
por: Propper, D J, et al.
Publicado: (2000)

Severe hypersensitivity reaction to etoposide phosphate: A case report
por: Cotteret, Camille, et al.
Publicado: (2020)

Pharmacokinetic Comparison of Three Different Administration Routes for Topotecan Hydrochloride in Rats
por: Jeong, Seung-Hyun, et al.
Publicado: (2020)

Topotecan and Cyclophosphamide in Adults with Relapsed Sarcoma
por: Blanchette, P., et al.
Publicado: (2012)

A phase II study of bryostatin 1 in metastatic malignant melanoma.
por: Propper, D. J., et al.
Publicado: (1998)

Topotecan given as a 21-day infusion in the treatment of advanced ovarian cancer
por: Gore, M, et al.
Publicado: (2001)

Phase I and pharmacokinetic study of the combination of topotecan and ifosfamide administered intravenously every 3 weeks
por: Kerbusch, T, et al.
Publicado: (2004)

Pharmacokinetics of Orbital Topotecan After Ophthalmic Artery Chemosurgery and Intravenous Infusion in the Swine Model
por: Requejo, Flavio, et al.
Publicado: (2023)

Successful local regional therapy with topotecan of intraperitoneally growing human ovarian carcinoma xenografts.
por: Pratesi, G., et al.
Publicado: (1995)

A study of the feasibility and accuracy of pharmacokinetically guided etoposide dosing in children.
por: Lowis, S. P., et al.
Publicado: (1998)

Impact of imatinib on the pharmacokinetics and in vivo efficacy of etoposide and/or ifosfamide
por: Rezaï, Keyvan, et al.
Publicado: (2007)

High-dose cyclosporin with etoposide--toxicity and pharmacokinetic interaction in children with solid tumours.
por: Bisogno, G., et al.
Publicado: (1998)

Pharmacokinetically guided dosing of carboplatin and etoposide during peritoneal dialysis and haemodialysis.
por: English, M. W., et al.
Publicado: (1996)

A phase I and pharmacokinetic study of intraperitoneal carboplatin and etoposide.
por: McClay, E. F., et al.
Publicado: (1993)

Myotilin, a New Topotecan Resistant Protein in Ovarian Cancer Cell Lines
por: Sterzyńska, Karolina, et al.
Publicado: (2018)

Commentary: Periocular topotecan for retinoblastoma
por: Sharma, Minal, et al.
Publicado: (2018)

Oral topotecan: bioavailability and effect of food co-administration
por: Herben, V M M, et al.
Publicado: (1999)

Dose and schedule-finding study of oral topotecan and weekly cisplatin in patients with recurrent ovarian cancer
por: Gelderblom, H, et al.
Publicado: (2001)

Phase II randomized study of PM01183 versus topotecan in patients with platinum-resistant/refractory advanced ovarian cancer
por: Poveda, A., et al.
Publicado: (2017)

Refractory Choriocarcinoma: Complete Response With Oral Etoposide
por: Dhanushkodi, Manikandan, et al.
Publicado: (2016)

Phase II study of sodium valproate in combination with oral etoposide in platinum-resistant ovarian cancer
por: Nakka, Thejeswar, et al.
Publicado: (2022)

First line combination chemotherapy with cisplatin and etoposide in advanced ovarian cancer.
por: Athanassiou, A. E., et al.
Publicado: (1989)

Periocular topotecan for vitreous seeds in retinoblastoma
por: Sthapit, Purnima R, et al.
Publicado: (2018)

Optimization of liposomal topotecan for use in treating neuroblastoma
por: Chernov, Lina, et al.
Publicado: (2017)

Reduced cellular accumulation of topotecan: a novel mechanism of resistance in a human ovarian cancer cell line.
por: Ma, J., et al.
Publicado: (1998)

Topotecan synergizes with CHEK1 (CHK1) inhibitor to induce apoptosis in ovarian cancer cells
por: Kim, Marianne K, et al.
Publicado: (2015)

Continuous-infusion verapamil with etoposide in relapsed or resistant paediatric cancers.
por: Cowie, F. J., et al.
Publicado: (1995)

Induction of thymidine phosphorylase as a pharmacodynamic end-point in patients with advanced carcinoma treated with 5-fluorouracil, folinic acid and interferon alpha
por: Braybrooke, J P, et al.
Publicado: (2000)

A phase II study of sequential carboplatin, paclitaxel and topotecan in patients with previously untreated advanced ovarian cancer
por: Guppy, A E, et al.
Publicado: (2004)

The Lipophilic Purine Nucleoside—Tdp1 Inhibitor—Enhances DNA Damage Induced by Topotecan In Vitro and Potentiates the Antitumor Effect of Topotecan In Vivo
por: Chernyshova, Irina A., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_g7gdvlcruc8lcv7gj7d24f2u5u